Neprilysin 2 (NEP2), a recently identified member of the M13 subfamily of metalloproteases, shares the highest degree of homology with the prototypical member of the family neprilysin. Whereas the study of the in vitro enzymatic activity of NEP2 shows that it resembles that of NEP as it cleaves the same substrates often at the same amide bonds and binds the same inhibitory compounds albeit with different potencies, its physiological role remains elusive because of the lack of selective inhibitors. To aid in the design of these novel compounds and better understand the different inhibitory patterns of NEP and NEP2, the x-ray structure of NEP was used as a template to build a model of the NEP2 active site. The results of our modeling suggest that the overall structure of NEP2 closely resembles that of NEP. Neprilysin 2 (SEP and NL-1) is a recently identified type II membrane-bound zinc-dependent metalloprotease (1-3). It is part of the M13 family of metalloproteases, which also comprises neprilysin (NEP, 1 EC 3.4.24.11) (4 -6), the endothelinconverting enzymes, ECE-1 (EC 3.4.24.71) (7) and ECE-2 (8), the Kell blood group antigen (9), the phosphate-regulating neutral endopeptidase on the X chromosome (10) and X-converting enzyme (11). Not only do all of the members of this family of metalloproteases share considerable sequence identities, suggesting a common ancestor as well as a common fold, NEP2, by far the closest homologue of NEP displays over 50% of overall protein sequence identity with NEP, a degree of homology that also suggests a common function (12).
and Asn 567 in substrate binding and catalytic activity of NEP2 and further show that the modifications in its S 2 pocket, particularly the presence therein of Leu 739 , account for a number of differences in inhibitor binding between NEP and NEP2.
Neprilysin 2 (SEP and NL-1) is a recently identified type II membrane-bound zinc-dependent metalloprotease (1) (2) (3) . It is part of the M13 family of metalloproteases, which also comprises neprilysin (NEP, 1 EC 3.4.24.11) (4 -6), the endothelinconverting enzymes, ECE-1 (EC 3.4.24.71) (7) and ECE-2 (8), the Kell blood group antigen (9) , the phosphate-regulating neutral endopeptidase on the X chromosome (10) and X-converting enzyme (11) . Not only do all of the members of this family of metalloproteases share considerable sequence identities, suggesting a common ancestor as well as a common fold, NEP2, by far the closest homologue of NEP displays over 50% of overall protein sequence identity with NEP, a degree of homology that also suggests a common function (12) .
The best characterized member of the family, NEP (13, 14) , was first identified as a kidney brush-border neutral endopeptidase slowly hydrolyzing [
125 I]iodoinsulin B chain (15) and rediscovered as an "enkephalinase" of cerebral membranes hydrolyzing the Gly 3 -Phe 4 bond of enkephalins (16) . Thereafter, it was shown to hydrolyze a number of biologically active peptides into inactive fragments in vitro, such as tachykinins (17) , bradykinin (18) , and atrial natriuretic peptides (19, 20) . The physiological implication of NEP in the inactivation of these messenger peptides was confirmed in vivo by the design and use of selective and potent inhibitors, e.g. thiorphan (21) (22) (23) (24) . These functions of NEP and the design of specific inhibitors thereof are of considerable interest, because the inhibitors of NEP have recently been introduced in human gastroenterologic (25) and cardiovascular (26) therapeutic fields.
Whereas NEP is widely distributed in peripheral tissues, NEP2 displays a highly restricted localization expressed exclusively in the central nervous system and testis (1, 27) . NEP2 also possesses the particularity of being coded for by a single gene with two major splice variants, one leading to a secreted protein by the insertion of a subtilisin-type cleavage site immediately after the transmembrane domain. This isoform (NEP2(s)) is expressed in round spermatids of the testis (1, 3) . The second isoform, mainly expressed in CNS, does not include the subtilisin-type cleavage site and thus leads to a membranebound protein (1, 28) . Expression of these isoforms in the endocrine corticotrope cell line AtT20 shows that both secreted and membrane-bound isoforms have identical catalytic activities and that they resemble the catalytic activity of NEP insofar, as they have been shown to cleave many of the same substrates, such as tachykinins and enkephalins, at the same amide bonds and with comparable kinetic parameters (28) . All of the transition state inhibitors of NEP also inhibit NEP2 activity. Thus, whereas the generic compound phosphoramidon binds both proteases with comparably high affinity (nanomolar range), thiorphan, a specific inhibitor of NEP also inhibits NEP2 at nanomolar concentrations but with an affinity 30 times higher for NEP than for NEP2 (28) .
The detailed study of the localization of NEP2 in the nervous system shows that it is widely distributed therein with a generally complementary pattern to that of NEP, although both enzymes are co-expressed in some areas, particularly in the neocortex and red nucleus (1, 27) . The most striking complementarity of NEP and NEP2 expression no doubt lies in the basal ganglia where the highest expression of NEP can be observed in caudate putamen and nucleus accumbens, regions that are devoid of NEP2 expression. The high expression of NEP in these regions had already been observed by immunocytochemistry (30) as well as by the quantification of NEP activity (31) and is in accordance with its potential role in the inactivation of endogenous tachykinins (32) and enkephalins of the striatonigral pathway (21) . However, this may not exclude a functional role of NEP2 in the inactivation of these neuropeptides, which it efficiently cleaves in vitro, because neurons of the striatonigral pathway project upon the substantia nigra pars reticulata, a NEP2-expressing region, devoid of NEP. The identification of NEP2 and the realization that once thought NEP-specific compounds are not as specific as expected bring forward the necessity to reassess the respective functions of NEP and NEP2 in the inactivation of endogenous messenger peptides, particularly in the brain. The design and synthesis of new discriminatory inhibitory compounds will not only constitute useful tools in this endeavor but may be of considerable interest in clinical treatment.
The three-dimensional structure of NEP has recently been elucidated by its co-crystallization with the inhibitory compound phosphoramidon (33) . This structure provides a new template to model the structure of metalloproteases of the M13 family clearly superior to the one available thus far, that of the bacterial enzyme thermolysin, which possesses little sequence identity with these mammalian metalloproteases, although it shares considerable similarities in its catalytic activity and inhibitory profile with NEP (34 -36) . Because of the high sequence identity between NEP and NEP2 and to better characterize the specific pharmacological profile of NEP2 as well as to aid in the design of potent and selective inhibitors of NEP2, we have used the three-dimensional structure of NEP to build and refine a model of the NEP2 active site. The obtained model was validated by site-directed mutagenesis of relevant residues in rNEP2(s), and the expression of these NEP2 mutants in AtT20 cells allowed us to study the impact of such substitutions on the kinetic parameters and affinities of the produced enzymes toward a series of substrates and inhibitory compounds.
EXPERIMENTAL PROCEDURES
Materials-The synthetic fluorogenic substrate Suc-AAF-AMC, dipeptides and related amidated dipeptides, and biological peptides were purchased from Bachem (Voisins le Bretonneux, France). Phosphoramidon was from Sigma (Saint Quentin Fallavier, France), and thiorphan and synthetic compounds I to IV were generous gifts from Denis Danvy and Thierry Monteil (Bioprojet, Paris, France).
Building and Refinement of a Three-dimensional Model of rNEP2-Amino acid sequences of hNEP (Swiss-Prot accession number P08473) and of rNEP2(s) were aligned using the ClustalW multiple alignment program (37) . A slow pairwise alignment using BLOSUM matrix series (38) and a gap-opening penalty of 15.0 were chosen for aligning the primary sequences. The three-dimensional model of NEP2 in complex with phosphoramidon was constructed by mutating the side chains of the amino acids in the hNEP-phosphoramidon structure (Protein Data Bank code 1dmt) to the respective side chains in NEP2. Standard geometries for the mutated side chains were given by the BIOPOLY-MER module of the Sybyl 6.8 package (TRIPOS Associates, Inc.). Whenever possible, the side chain torsional angles were kept to the values occurring in hNEP. Otherwise, a short scanning of side chain angles was performed to remove steric clashes between the mutated side chain and the other amino acids. Insertions/deletions occurred only in loops but not in secondary structure elements (␣-helix, ␤-sheet). The insertions/deletions in the loops were achieved through a simple knowledgebased loop search procedure using the LOOPSEARCH module of the SYBYL package (TRIPOS Associates, Inc). In this procedure, a set of 1478 high resolution x-ray structures was searched for loops of similar length and similar distance between the C␣ atoms of the residues delimiting the loop window. The loop showing the highest homology and the lowest root mean square deviations was then selected for insertion in the model. After the heavy atoms were modeled, all of the hydrogen atoms were added and the protein coordinates were then minimized with AMBER 6.0 (39) using the AMBER95 forcefield (40) . The phosphoramidon molecule was parameterized for AMBER 6.0 using a previously described procedure (41) . The minimizations were carried out by 2,000 steps of steepest descent followed by conjugate gradient minimization until the root mean square gradient of the potential energy was Ͻ0.05 kcal⅐mol Ϫ1 ⅐Å Ϫ2 . A twin cut-off (10.0 and 15.0 Å) was used to calculate non-bonded electrostatic interactions at every minimization step, and the non-bonded pair list was updated every 25 steps. A distance-dependent (⑀ ϭ 4r) dielectric function was used.
Ligand Docking-The three-dimensional coordinates of compound II obtained as previously described (42) were automatically docked into the above-described ligand-free coordinates of NEP2 as well as to those of NEP using 7-8 times speed-up parameters of the GOLD 2.0 docking tool (43) . To account for a proper coordination to the zinc ion, a distance constraint was defined between the zinc and the thiol sulfur atom of compound II assuming an intermolecular distance between 1.8 and 2.1 Å and a spring constant of 5 kcal⅐mol Ϫ1 ⅐Å Ϫ2 . To further speed up the calculation, the genetic algorithm docking was stopped when the top three solutions were within a root mean square deviation of 1.5 Å.
Site-directed Mutagenesis of rNEP2(s)-The rNEP2(s)-expressing plasmid, pcDNA-rNEP2(s), has been previously described (28) . Doublestranded mutagenesis of rNEP2(s) was carried out using the Transformer site-directed mutagenesis kit (Clontech) following the manufacturer's instructions. All of the constructs were completely sequenced using an automated Licor sequencer to confirm the authenticity of the different mutations as well as the integrity of the NEP2 coding sequence.
Expression of Wild-type and Mutated Forms of rNEP2(s) in AtT20
Cells-AtT20 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum. Transient transfections of wild-type and mutated rNEP2(s) constructs were performed using Superfect (Qiagen, Courtaboeuf, France) according to the supplier's instructions. After 3 h at 37°C, the transfection medium was replaced by a low protein, serum-free medium, CHO-S-SFM II (Invitrogen). Routinely, the conditioned media were collected 72 h post-transfection and concentrated 10-fold using the centrifugal filter device (Centriprep 30, Amicon). Cells from 140-mm plates were scraped, harvested in ice-cold Hepes buffer (100 mM, pH 7.2, 0.1 mM phenylmethylsulfonyl fluoride) and disrupted with a Polytron (Kinematica, Lucerne, Switzerland). Membranes were obtained by centrifugation (30,000 ϫ g for 1 h), resuspended in Hepes buffer, and sonicated (twice for 5 s).
Antibody Production and Immunoblotting-The complete C-terminal region of NEP2 (from residue 83 to 769, see Fig. 1 ) was amplified using the following oligonucleotides: 5Ј-GCGAATTCGACATCTGTACTAC-CCC-3Ј and 5Ј-GCCGCTCGAGTCGATTCATAGGGTGCAT-3Ј, where nucleotides in italics correspond to added EcoRI and XhoI cloning sites, respectively. After digestion with the appropriate restriction enzymes, the amplicon was subcloned into the pET24a vector (a kind gift from Dr. J. C. Barale, Pasteur Institute, Paris, France) and grown in BL21 cells and the corresponding 85-kDa protein was purified and sent to Eurogentech for an immunization protocol.
For immunoblotting experiments, samples were diluted in loading buffer (0.1 M Tris-HCl, pH 6.8, 15% glycerol, 3% SDS, 3% ␤-mercaptoethanol, 0.02% bromphenol blue), subjected to SDS/PAGE on 7.5% polyacrylamide gels (Bio-Rad), and transferred onto polyvinylidene difluoride membranes (Amersham Biosciences). After 1 h in Tris-buffered saline (0.1 M Tris-HCl, 0.9% NaCl, pH 7.4) containing 0.2% Tween 20 and 5% bovine serum albumin, blots were incubated with the NEP2-specific polyclonal antibody (diluted 1/10,000) for 16 h at 4°C. Immunoblots were revealed after a 1-h incubation with the appropriate horseradish peroxidase-coupled IgG (diluted 1/3000) using Supersignal (Perbio Science France, Bezons, France).
Enzyme Activity Assays and Inhibitory Potencies-Enzymatic activities of the wild-type and mutated forms of rNEP2(s) were assayed essentially as described in Rose et al. (28) . For K m determinations, the incubation mixtures were comprised of 20 -50 g of the concentrated conditioned media and from 7.8 to 1000 M Suc-AAF-AMC in 100 l of 100 mM Hepes buffer, pH 7.2, containing 0.15 M NaCl and 0.01% Triton X-100. Incubations were allowed to proceed for 60 min at 37°C followed by a 60-min incubation with an excess of aminopeptidase M (Pierce) to release fluorescent AMC. The enzyme concentrations were quantified by densitometric analysis of immunoblots using the known amounts of purified NEP2 standards (28) .
Inhibitory potencies were determined as follows. After a 15-min preincubation with 20 -50 g of conditioned media and inhibitors or dipeptides in 100 l of 100 mM Hepes buffer, pH 7.2, containing 0.15 M NaCl, 0.01% Triton X-100, a 20 M concentration of the model sub-strate, Suc-AAF-AMC, was added and the reaction was allowed to proceed for 60 min at 37°C followed by a 60-min incubation with aminopeptidase M. For inhibitory potencies of compounds against NEP, a pure recombinant soluble form of human NEP was used as previously described by Rose et al. (28) . Inhibitors were tested at concentrations ranging from 1 pM to 10 M, and peptides from 1 M to 1 mM. The K i values were calculated from the IC 50 values using the Cheng and Prussoff equation.
Statistical Analysis-The Student's t tests were performed using the Instat program.
RESULTS
The NEP2 isoforms, NEP2(m) and NEP2(s), are identical in their large C-terminal core, possess identical enzymatic properties, and are inhibited by the same compounds with comparable potencies (28) . To ease the study and production of NEP, a secreted form of this enzyme was engineered (secNEP) (44) and was found to have the same enzymatic properties as the natural enzyme. It is this type of construct that was used in the crystallographic study of NEP (33) . The model of the active site of NEP2 being based on the alignment of the C-terminal domains of model and template thus applies to both isoforms of NEP2 on one hand as well as to rNEP2 and human NEP2 on the other hand, because both active sites align perfectly (100% sequence identity, data not shown). Coordinates used for NEP2 correspond to rNEP2(s), because this isoform was used in the site-directed mutagenesis studies.
Description of the NEP2 Active Site Model: Comparison to the NEP Active Site Structure-The overall protein sequence similarity between rNEP2(s) and hNEP is of 67% with the highest degree of homology located in the distal C-terminal part of the protein, which contains the active-site consensus sequence HEXXH (75% over the last 250 amino acids). Because this high degree of sequence similarity between the two proteins strongly suggests that they have evolved from a common ancestor, we used the recently solved structure of hNEP as a template to build and refine a NEP2 active site model as described under "Experimental Procedures." The three-dimensional structure of NEP2 closely resembles that of NEP, because it is constituted by two domains: the first (domain 1) containing the active site and a second (domain 2) presumably acting as a molecular sieve with both domains separated by interdomain linker fragments (data not shown). Coordinates of phosphoramidon were taken from the respective hNEP complex and merged into the NEP2 model. The active site of both enzymes was then designed as any amino acid included into a 6-Å radius sphere centered on the inhibitor. The NEP2 active site model thus obtained was highly similar to the hNEP structure, both active sites displaying 97 and 86% amino acid sequence similarity and identity, respectively (Fig. 1) .
The conserved zinc binding motif, HEITH, from template and model is well superimposed. The zinc ion is coordinated in an approximately tetrahedral geometry ( oxygen atom of Ala 568 of NEP2 (Ala 543 in hNEP) is hydrogenbonded with the peptide amide group of the PЈ 1 residue of phosphoramidon, and the side chain of Asn 567 of NEP2 (Asn 542 in hNEP) forms two hydrogen bonds with the amide and carboxyl groups of the PЈ 2 residue of the inhibitor ( Fig. 2A) . Additionally, the side chain of Arg 131 of NEP2 (Arg 102 in hNEP) does not allow a direct hydrogen bond but may form a two watermediated interaction with the terminal carbonyl group of the inhibitor as in hNEP.
NEP and NEP2 cleave peptidic substrates at the N terminus of aromatic or large hydrophobic residues, which constitute the PЈ 1 amino acid in the P 2 -P 1 -PЈ 1 -PЈ 2 commonly accepted Schechter and Berger nomenclature. The specificity of these enzymes is therefore the result of specific interactions of the PЈ 1 and PЈ 2 side chains within the SЈ 1 The phosphoramidon-NEP2 active site complex model allows us to propose a schematic representation of the peptidic substrate interactions with NEP2 ( Fig. 2A) , a model in which overall these interactions are highly similar to those of NEP. However, the results presented here bring forward the fact that the SЈ 2 subsite of NEP2 may differ from that of NEP due to the presence of the Ser 133 and particularly Leu 739 in lieu of the two glycine residues found in the corresponding positions of the NEP sequence, substitutions which may contribute to the pharmacological differences between the two proteases.
Exploration of the SЈ 2 Subsite of NEP2 by Site-directed Mutagenesis of rNEP2(s)-We have recently shown that NEP2
isoforms expressed in AtT20 cells are synthesized in the endoplasmic reticulum as inactive precursors of 110 kDa, which must exit this compartment in order to become active. The activation of the NEP2 isoforms is concomitant with their acquisition of complex sugars reflected by an increase in their molecular weights. In the case of rNEP2(s), membranes only express the inactive 110-kDa form, whereas the mature and active enzyme is entirely recovered in the medium as a 125-kDa protein. Enzymatic activity of wild-type rNEP2(s) thus is detected exclusively in the conditioned media of transfected AtT20 cells and can be monitored using the fluorogenic model substrate Suc-AAF-AMC (28) . Because no significant differences between the SЈ 1 subsites of NEP and NEP2 were observed, the SЈ 2 subsite, the region in which differences between the two metalloproteases were brought to light by the here (28), is expressed both in the membrane fraction and in the conditioned medium of transfected AtT20 cells as either a 110-kDa membrane-bound protein or an ϳ125-kDa band in the conditioned medium (Fig.  3) . Mutants of the SЈ 2 subsite, rNEP2(s)-R131M and rNEP2(s)-N567G, produced the same molecular weight bands when expressed in AtT20 cells, suggesting normal processing of these proteins (Fig. 3) . Furthermore, as shown in Table I , the introduction of these mutations in the NEP2 active site produced enzymatically active proteases, however, with altered catalytic properties.
Kinetic values of rNEP2(s)-R131M were not different from wild type using the model substrate Suc-AAF-AMC in which the AMC molecule blocks its C-terminal end. Indeed, neither the K M (p ϭ 0.21) nor the k cat (p ϭ 0.18) of this mutant toward the fluorogenic model substrate is significantly different from wild type. Further exploration of the catalytic site of this mutant using inhibitory dipeptides (Table II) , however, uncovers the role of Arg 131 in substrate binding, which in the proposed model ( Fig. 2A) is hydrogen-bonded to the C-terminal group of the peptidic substrate or inhibitor. Dipeptides are considered inhibitory because they bind the active site of metalloproteases in the SЈ 1 and SЈ 2 subsites and thus inhibit their catalytic activity monitored here with the model fluorogenic substrate. Inhibitory potencies of dipeptides or their respective amidated counterparts were determined against wild type and the R131M mutant (Table 2) . On one hand, inhibitory potencies of natural dipeptides were significantly decreased against rNEP2(s)-R131M as compared with the wild-type enzyme (6-fold decrease for Val-Phe (p ϭ 0.044) and a 4.5-fold one for Leu-Met (p ϭ 0.023), reflecting a decrease in the affinity of these dipeptides toward the mutant. On the other hand, although rNEP2(s)-R131M showed no preference for the natural dipeptides over their amidated forms (p Ն0.5), wild-type rNEP2(s) displayed a strong decrease in its binding of amidated Leu-Met or Val-Phe (a 9-fold (p ϭ 0.0061) and 6-fold (p ϭ 0.0036) decrease, respectively), reaching comparable values as those obtained for rNEP2(s)-R131M, clearly demonstrating that peptide amidation abrogates binding of the PЈ 2 residue to Arg 131 but not the binding of the dipeptide itself. The involvement of Arg 131 in the binding of residues in PЈ 2 was further confirmed by the study of the affinities reflected by their inhibitory potencies (K i ) against the model fluorogenic substrate of a series of bioactive peptides previously shown to be efficiently cleaved by NEP2 (28) . As for amidated dipeptides, the binding of substance P or cholecystokinin-8, both naturally amidated peptides, was unaffected by the mutation (Table III) . In the same manner, wild-type rNEP2(s) displayed a significant (p ϭ 0.0046) 11-fold preference for [Leu 5 ]enkephalin over its amidated counterpart, a preference that was lost to the rNEP2(s)-R131M mutant (Table III) . The angiotensin I or bradykinin affinities were equally unaffected by the loss of the Arg 131 residue in NEP2. These results show that Arg 131 is not involved in the binding of substrates, which are subject to endoproteolysis (reflected by angiotensin I cleavage) as opposed to those cleaved by the dipeptidyl carboxypeptidase activity of NEP2 (e.g. [Leu 5 ]enkephalin and CCK1-6) whose binding is affected by the loss of this charged residue. However, the observed results suggest that Arg 131 does not play an essential role in this latter activity as PЈ 2 residues, which cannot form any hydrogen bond with it (because of charge repulsion) (i.e. the ultimate arginine residue of bradykinin), bind with high affinity, the active site of NEP2 or of its R131M mutant (Table III) . Taken together, these results show that the R131M mutation does not affect the integrity of the rNEP2(s) structure and strongly argue for a role of Arg 131 in the binding of the free and conditioned culture media (M) from control (C), wild-type (WT), and mutated rNEP2(s)-transfected AtT20 cells were separated on a 7.5% SDS-polyacrylamide gel under reducing conditions and immunoblotted with a NEP2-specific polyclonal antibody. Membrane fractions contain an immunoreactive band of 110 kDa corresponding to inactive NEP2, whereas the conditioned media display a 125-kDa protein that corresponds to fully glycosylated, secreted, and active NEP2. carboxylate group of substrates, although this binding is dependent on the nature of the PЈ 2 residue and of its interactions within the SЈ 2 subsite. Expression of rNEP2(s)-N567G in AtT20 cells and study of its catalytic activity using the model substrate showed that the K M of this mutant toward the fluorogenic substrate was significantly increased (p Յ 0.001) as compared with the wild type enzyme, whereas its k cat decreased by ϳ3-fold (p ϭ 0.0005), yielding an enzyme with a 43-fold decrease in its specificity constant (Table I ). The significant effect of this mutation on the catalytic parameters of NEP2, on one hand, confirms the critical role of the Asn 567 residue in hydrolysis and in binding of the substrate as had been previously demonstrated for NEP (46) and, on the other hand, lends further credence to our proposed model of the NEP2 active site.
To further test our model, the side chains of the Ser 133 and Leu 739 residues of the SЈ 2 subsite of NEP2 were replaced by glycine residues to explore whether the produced enzyme would acquire a NEP-like pharmacological profile. The expression of rNEP2(s)-S133G, rNEP2(s)-L739G, and that of the double mutant rNEP2(s)-S133/L739G in AtT20 cells followed by immunoblotting experiments revealed that these constructs produced normally secreted NEP2 proteins (Fig. 3) . However, although these mutant forms of rNEP2(s) possessed enzymatic activity, the K M of rNEP2(s)-S133G was significantly increased (p ϭ 0,025), whereas its k cat was reduced 7-fold (p ϭ 0.001), yielding an enzyme with a 22-fold decrease in its specific activity, suggesting an effect of this mutation both in substrate binding as well as on hydrolysis (Table I) . On the contrary, the rNEP2(s)-L739G and the double mutant displayed specificity constants toward the model fluorogenic substrate increased by 3.5-and 2-fold, respectively, reaching values comparable to those of NEP previously determined in the same conditions to be ϳ30 (Table I) (28) . Moreover, this increase of the specificity constant was essentially the result of an increase in k cat (although only the increase of the k cat of L739G reaches significance (p ϭ 0.014) suggesting that, although the binding of the substrate is not affected by these mutations, the catalytic activity is increased (Table I) .
To explore the influence of the Ser 133 and Leu 739 residues of the SЈ 2 subsite of NEP2 on inhibitor binding, K i values of various synthetic compounds were determined against these mutants and compared with those of wild-type NEP2 and NEP (Table IV) . Moreover, to assess the specific role of these residues in the pharmacological differences between NEP2 and NEP, the effects of the S133G and L739G mutations were also compared with those of residues equivalent in NEP2 and NEP, i.e. the R131M and N567G mutants (Arg 131 corresponding to Arg 102 in NEP and Asn 567 to Asn 542 ). As previously shown (28), all of the transition-state inhibitors of NEP inhibit NEP2 activity, although both metalloproteases do not display an identical pharmacological profile. Thus, phosphoramidon and compound III are strong equipotent inhibitors of both peptidases (ϳ1 nM for phosphoramidon and 0.5 nM for compound III). However, in the cases of thiorphan compounds I, II, and IV, the K i values strongly differ between NEP and NEP2 (K i rNEP2(s)/K i hNEP ϭ 30 for thiorphan, 14 for compound I, 600 for compound II, and 60 for compound IV). Whereas the inhibitory potencies of all of the compounds tested against the rNEP2(s)-N567G mutant were modified, no tendency of a change toward NEP values could be detected (Table III) . Although the same observation can be made for the R131M mutant, it is interesting to note that the mutation of this residue had a severe impact on the binding of two compounds, thiorphan and compound II (Table III) , suggesting that this residue is also involved in inhibitor binding in NEP2.
TABLE IV Inhibitory potencies of a series of compounds against wild-type and mutant forms of NEP2 compared to NEP
The model fluorogenic substrate Suc-AAF-AMC (20 M) was used to evaluate the inhibitory potencies of a series of compounds systematically modified in PЈ 1 and PЈ 2 based on the structure of thiorphan against the activities of mutants of the rNEP2(s) SЈ 2 subsite. These values are also compared with NEP. Numbers the are mean values of at least two independent determinations. K i values of the double S133G/L739G NEP2 mutant in boldface are statistically different from wild type.
Phosphoramidon, an equipotent compound against NEP and NEP2, did not display any significant change in its affinity toward the rNEP2(s)-S133G, rNEP2(s)-L739G, and rNEP2(s)-L739GϩS133G mutants. However, in the case of compound III, the second equipotent compound tested, a significant decrease in its K i value toward the double S133G/L739G mutant (p ϭ 0.0176) was observed, a value that furthermore became slightly different from that of NEP (p ϭ 0.43), toward a better affinity. These results show that identical SЈ 2 subsites, as defined by co-crystallization on one hand and our modeling on the other, can bind a given compound differently, thus suggesting cooperativity in the various subsite interactions of a given compound as other interactions must come into play in or outside this SЈ 2 subsite mutant of NEP2 for it to bind compound III with a higher affinity than NEP.
Variations of K i values of the NEP2(s) mutants toward NEP values are observed among the discriminating compounds, the only exception being thiorphan whose inhibitory potency toward the NEP2 double mutant is identical to that of wild-type NEP2 (p ϭ 0.82). Indeed, the K i values of compounds I and IV toward the rNEP2(s)-S133G mutant are decreased toward values obtained with NEP, although results obtained with this mutant are not as flagrant as those obtained with rNEP2(s)-L739G. The inhibitory potencies of compounds I, II, and IV against the L739G NEP2 mutant are almost identical to those of NEP, confirming in a clear-cut manner the contribution of Leu 739 in the pharmacological differences between NEP and NEP2. Although the result obtained with the S133G mutant are to be taken cautiously because of its decreased specific activity, it is interesting to note that the K i values obtained with the double mutant (rNEP2(s)-S133G/L739G), which produces an active enzyme with kinetic values comparable to those of rNEP2(s)-L739G, are always lower than those of NEP2 proteins containing either mutation alone, suggesting some kind of cooperative effect of the Ser 133 and Leu 739 residues in inhibitor binding. Indeed, using the discriminating NEP/NEP2 compounds, the obtained K i values toward the NEP2 double mutant on one hand are significantly different from the ones against wild type NEP2 (p ϭ 0.035, 0.001, and 0.016 for compounds I, II, and IV, respectively). On the other hand, these same values are the reflection of the acquired NEP-like properties of the NEP2 double mutant as they reach values either statistically indistinguishable from those of NEP (p ϭ 0.056 and 0.14 for compounds I and II, respectively), or, in the case of compound IV, 4-fold better than against NEP (p ϭ 0.12), once again bringing to light the importance of other unidentified subsite interactions.
DISCUSSION
Until recently, the only structure available for the modeling of zinc-metalloproteases of the M13 subfamily was that of thermolysin, which, has little sequence homology with these proteases, although it shares many enzymatic properties with NEP and a common active site structure (34 -36) . Therefore, it constitutes a poor template, seeing it is a distant bacterial enzyme (from Bacillus stearothermophilus) that does not contain all of the catalytically important residues of NEP, and is significantly shorter in length than NEP and its homologues (316 amino acids for thermolysin versus 743 for hNEP). The recent disclosure of the structure of the ectodomain of NEP obtained by x-ray crystallography (33) provides a new and relevant template to model closely related members of the M13 subfamily and, in particular, the recently characterized NEP2 neuropeptidase (1) (2) (3) . The obtained active site model of NEP2 (Fig. 2) shows that the structure of these two metalloproteases share many features as expected, on one hand, by their high sequence identity (1) and, on the other hand, by their similar specific activities and inhibitory profiles (28) , and Arg 717 in hNEP, respectively). The definition of the organization of these amino acids into subsites further reveals that, whereas the SЈ 1 subsite of NEP2 and NEP are basically constituted by the same residues, their SЈ 2 subsites contain amino acid substitutions that could account for pharmacological differences between these two proteases. Indeed, in this subsite, the NEP and NEP2 metalloproteases differ by two amino acids with Ser 133 and Leu 739 replacing two glycine residues in NEP, a difference that warranted further exploration of this subsite by site-directed mutagenesis.
For these experiments, we used the secreted isoform of NEP2 (NEP2(s)), which naturally sheds its C-terminal domain in the extracellular milieu (28) and which corresponds to the genetically engineered form of NEP produced for its x-ray crystallographic study (secNEP) (44, 28) . Mutation of the Arg 131 or Asn 567 residues of the NEP2 active site to methionine or glycine, respectively, yielded active, normally secreted NEP2 mutants (Fig. 4 and Table I ). As proposed in our model, the results displayed in Tables I and II suggest a similar role of these two amino acids in NEP2 and NEP (Fig. 2) . Indeed, the mutation of these residues in NEP (46) had previously shown a stronger interaction of Asn 542 than Arg 102 with the substrate. The 10-fold decrease in affinity of the rNEP2(s)-N567G mutant toward the model substrate confirms the involvement of this residue in substrate binding with this effect being furthermore comparable to a ϳ14-fold decrease in affinity observed for a NEP-N542G mutant (45) (46) . Hydrolysis was also affected by the introduction of the N567G mutation within the NEP2 sequence, underlying the critical role of this residue in catalytic activity. Whereas the Asn 567 residue is revealed to be essential to the NEP2 catalytic activity, the effects of the R131M mutation were more subtle as they were, for example, not significant on model substrate activity (Table I) . However, NEP and NEP2 have been shown to possess a dipeptidyl carboxypeptidase activity (47, 48, 28) and, in NEP, Arg 102 was demonstrated to bind the free carboxylate of substrates (or inhibitors) and thus direct cleavage toward their C-terminal end (46, 48 -50) . Of the various Arg 102 NEP mutants previously produced, an R102M mutant tested against various Phe-X dipeptides showed that their inhibitory potencies were generally decreased by this mutation compared with wild-type NEP (46), as observed here for NEP2 (Table II) . The affinity of Phe-Gly toward NEP, the binding of which was of the most severely affected by the mutation of Arg 102 , decreased from the micromolar to millimolar range for wild-type and R102M NEP mutant, respectively, a difference in binding observed with NEP2 and thiorphan, which is constituted by a phenylalanine in PЈ 1 and a glycine residue in PЈ 2 (Table IV) (46) . The loss of this active site arginine residue in both NEP and NEP2 (Arg 102 or Arg 131 , respectively) has an equivalent impact on the binding of PЈ 2 phenylalanine residues (5.5-versus 6-fold decrease in the binding of X-Phe to NEP and to NEP2, respectively), and the binding of enkephalins to NEP has also been shown to be compromised by the loss of (50) , is unaffected by the loss of this active site arginine residue (e.g. angiotensin I), underlying the non-essential and very variable nature of this interaction. Variability again reflected by the binding of bradykinin that, although it possess a PЈ 2 arginine residue (2Phe 8 -Arg 9 ), which should be repelled by the positive charge of Arg 131 , binds NEP2 and its R131M mutant with equally high affinity (Table II) . The ensemble of these results not only validates the modeling process but confirms for the first time the implication of the Asn 567 residue of NEP2 in its catalytic activity as well as that of Arg 131 in the dipeptidyl carboxypeptidase activity of this metalloprotease.
The differences brought to light between the NEP and NEP2 SЈ 2 subsites could account for their related but distinct inhibitory profiles. Indeed, whereas NEP has a high affinity for compounds that possess a large hydrophobic moiety in either PЈ 1 and/or PЈ 2 , NEP2 does not tolerate large side chains in PЈ 1 . This is reflected by the affinities of compounds II and IV (biphenyl moiety in PЈ 1 ), which are 600 and 60 times more potent against NEP, respectively (Table III) . Although these data suggest that differences between the two enzymes should lie within the PЈ 1 subsite, both the modeling and docking (Figs. 2  and 4 ) results provide another explanation to these data. Indeed, the docking of compound II in the active site of the NEP crystal (Fig. 4) reveals that the biphenyl moiety of this compound adopts a conformation where it partly fills the SЈ 2 subsite of the protease. This could provide an explanation for the loss of affinity, although still in the nanomolar range, of compound II versus compound IV toward NEP where the indole moiety in PЈ 2 of compound IV fills the SЈ 2 subsite of NEP and hinders binding of the PЈ 1 biphenyl moiety in the same subsite. Although NEP2 binds compounds with large indole moieties in PЈ 2 with high affinity (e.g. phosphoramidon and compound III), it does not bind compounds with biphenyl moieties in PЈ 1 whether they are with (compound IV) or without (compound II) large P' 2 moieties. These results suggest that, if the adopted conformation of the biphenyl moiety in the active site of NEP2 is the same as that of NEP, it does not fit as well in the NEP2 SЈ 2 subsite in which the presence of Ser 133 and Leu 739 could modify access or binding. This is further evidenced by the decrease in affinity between compounds III and IV (160-fold) in which the indole moiety in PЈ 2 is probably to fill the SЈ 2 subsite of NEP2.
Site-directed mutagenesis of the two differential amino acids in this subsite and transfection of these mutants yielded secreted active NEP2 mutants ( Fig. 3 and Table I ). Recently, we have compared the catalytic properties of NEP and NEP2 using a series of model and bioactive peptides (28) and have shown that, although they both bind the model fluorogenic substrate Suc-AAF-AMC with comparable affinities, for instance, the catalytic constant (k cat ) of NEP is approximately four times that of NEP2 (Table I) . Although the kinetic values obtained with the S133G mutant of NEP2 were significantly different from those of wild-type NEP2, they were not any closer to those previously obtained for wild-type NEP, thus not allowing to infer a NEP/NEP2-differentiating function of this residue. Nevertheless, the significant decrease of affinity of the substrate toward this mutant does suggest that this residue may be involved in the binding of the substrate (or inhibitor). Whereas the specific activity of this latter mutant was significantly decreased, the ones of the L739G and S133G/L739G double mutant were both increased toward NEP values. Moreover, this effect was mainly the result of an increase in their catalytic activity, giving these mutants a NEP-like profile, i.e. both a high affinity and catalytic constant toward the model substrate. Furthermore, the pharmacological properties of these two mutants are shown to acquire NEP-like qualities toward discriminatory NEP/NEP2 compounds, the only exception being thiorphan. Indeed, the replacement of the large side chain of Leu 739 by a glycine residue in SЈ 2 of NEP2 allows the binding of compounds I, II, and IV with affinities either closer to or identical to those of NEP. Values toward the double mutant (S133G/L739G) are either equal to or better, i.e. closer to those of NEP, than the ones obtained with the L739G mutant, suggesting some kind of effect of the Ser 133 residue on inhibitor binding, an effect that is particularly apparent with compounds that acquire better binding properties to the NEP2 double mutant than to NEP (i.e. Compounds III and IV in Table IV) .
The ensemble of the results seem to point to the fact that specific interactions within a particular subsite depend on the nature of the residue as well as on the manner in which it is "presented," i.e. on the conformation of the substrate or inhibitor. For instance, the inhibitory potency of compound IV with an indole moiety in PЈ 2 position toward the S133G mutant is increased Ͼ10-fold toward a value closer to that of NEP, whereas the same PЈ 2 moiety in the context of the phosphoramidon molecule loses affinity toward this same mutant. Although the proposed model of the NEP2 active site may have some limits, as reflected by the results obtained with thiorphan on one hand and the ambiguous results of the S133G mutant on the other, it may be interesting to note that, in the cases of thiorphan and compound II, these ambiguous results can be explained by the unsuspected involvement of Arg 131 in inhibitor binding, the removal of which (in the R131M mutant) abolishes their binding to NEP2. Furthermore, this observation seems to be specific to NEP2 as it was not previously observed with Arg 102 mutants of NEP and as revealed by the recent co-crystallization of NEP with different inhibitory compounds, which show no charged residues of the NEP SЈ 2 subsite as being directly involved in inhibitor binding (51) .
The template used here to model the NEP2 active site was that of NEP bound to phosphoramidon, an equipotent inhibitor of NEP and NEP2. Because enzymes, like receptors, adopt different conformational states when bound to different molecules (51), it is likely that this model, just as the crystal, may not allow the unraveling of all of the different residues involved in inhibitor (and substrate) binding. Nevertheless, the proposed three-dimensional structure of the NEP2 active site based on the x-ray structure of NEP together with site-directed mutagenesis results enabled us to put forward the first reasonably accurate active site model of NEP2, which provides important information for the synthesis of new specific inhibitory compounds of this protease. We have validated the function of Arg 131 in the dipeptidyl carboxypeptidase activity of NEP2 as well as unraveled its function in the binding of some inhibitory compounds. The participation of Asn 567 in both substrate binding (and to a lesser extent inhibitor) and hydrolysis is equally confirmed. Finally, Leu 739 and Ser 133 were identified and validated as unsuspected and important amino acids to the enzymatic specificity of NEP2.
